Journal article · 2026

Checkpoint inhibitor combinations: the trial-to-approval gap

Fahad A. Benthani, Samik Upadhaya, Alicia Yiran Zhou

Nature Reviews Drug Discovery · Published 4 November 2026 · DOI 10.1038/d41573-026-00174-7

View at the publisherCite this paper

In brief

“Checkpoint inhibitor combinations: the trial-to-approval gap” is a 2026 journal article by Fahad A. Benthani and 2 co-authors, published in Nature Reviews Drug Discovery. OpenAlex counts 0 citations as of 17 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
Authors
3

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Benthani, F. A., Upadhaya, S., & Zhou, A. Y. (2026). Checkpoint inhibitor combinations: the trial-to-approval gap. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00174-7

MLA 9

Benthani, Fahad A., et al. “Checkpoint inhibitor combinations: the trial-to-approval gap.” Nature Reviews Drug Discovery, 2026. https://doi.org/10.1038/d41573-026-00174-7.

Chicago

Benthani, Fahad A., Samik Upadhaya, and Alicia Yiran Zhou. 2026. “Checkpoint inhibitor combinations: the trial-to-approval gap.” Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00174-7.

Harvard

Benthani, F. A., Upadhaya, S. and Zhou, A. Y. (2026) ‘Checkpoint inhibitor combinations: the trial-to-approval gap’, Nature Reviews Drug Discovery. doi:10.1038/d41573-026-00174-7.

IEEE

F. A. Benthani, S. Upadhaya, and A. Y. Zhou, “Checkpoint inhibitor combinations: the trial-to-approval gap,” Nature Reviews Drug Discovery, 2026, doi: 10.1038/d41573-026-00174-7.

BibTeX

@article{benthani2026checkpoint,
  title     = {{Checkpoint inhibitor combinations: the trial-to-approval gap}},
  author    = {Benthani, Fahad A. and Upadhaya, Samik and Zhou, Alicia Yiran},
  journal   = {Nature Reviews Drug Discovery},
  year      = {2026},
  doi       = {10.1038/d41573-026-00174-7},
  url       = {https://doi.org/10.1038/d41573-026-00174-7}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • immune checkpoint inhibitors
  • combination therapy
  • drug approval
  • cancer immunotherapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Benthani, F. A., Upadhaya, S., & Zhou, A. Y. (2026). Checkpoint inhibitor combinations: the trial-to-approval gap. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00174-7

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Fahad A. Benthani, Samik Upadhaya, Alicia Yiran Zhou.

What is the DOI of this paper?

10.1038/d41573-026-00174-7, permanently at https://doi.org/10.1038/d41573-026-00174-7. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.